Ironwood Pharmaceuticals (IRWD) Cash from Financing Activities (2010 - 2025)

Ironwood Pharmaceuticals has reported Cash from Financing Activities for 16 years, with the latest figure at $122000.0 in Q4 2025.

• Quarterly Cash from Financing Activities rose 100.82% year-over-year to $122000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $216000.0 (up 100.2% YoY) and the FY2025 annual result came in at $216000.0, up 100.2% from the prior year.
• Cash from Financing Activities climbed to $122000.0 in Q4 2025 per IRWD's latest filing, from $88000.0 in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $399.1 million in Q2 2023 and troughed at -$150.3 million in Q2 2022.
• A 5-year average of -$3.8 million and a median of $6000.0 in 2025 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2021 and 2023: Cash from Financing Activities soared 820.0% in 2021, then slumped 9508.78% in 2023.
• Over 5 years, Cash from Financing Activities stood at -$18.6 million in 2021, then soared by 115.1% to $2.8 million in 2022, then tumbled by 1914.11% to -$50.9 million in 2023, then jumped by 70.75% to -$14.9 million in 2024, then jumped by 100.82% to $122000.0 in 2025.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $122000.0, $88000.0, and $6000.0 for Q4 2025, Q2 2025, and Q1 2025 respectively.